Word abonnee en neem Beursduivel Premium
Rode planeet als pijlen grid met hoorntjes Beursduivel
Uitgebreid zoeken
Aandeel

BIOSENIC BE0974280126

Laatste koers (eur)

0,021

  • Verschill

    +0,001 +3,43%

  • Volume

    449.651 Gem. (3M) 1,2M

  • Bied

    0,021  

  • Laat

    0,021  
+ Toevoegen aan watchlist

Forum Bone Therapeutics geopend

319 Posts
Pagina: «« 1 2 3 4 5 6 ... 16 »» | Laatste | Omlaag ↓
  3. [verwijderd] 26 mei 2017 11:24

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    De volledige fase 2 resultaten voor Allob bij vertebrale fusie worden in het tweede kwartaal van 2017 verwacht. Zou de stijging van de laatste dagen hiermee te maken kunnen hebben?
  6. Bassie152 29 mei 2017 16:33

    • Bassie152

      Lid sinds: 19 mrt 2017

      Laatste bezoek: 19 apr 2024

    • Aanbevelingen

      Ontvangen: 20

      Gegeven: 29

    •    Aantal posts: 15

    Bone Therapeutics strengthens Board with the appointments of Steve Swinson and Damian Marron as Non-Executive DirectorsSenior executives with international experience in orthopaedics and cell therapy

    Gosselies, Belgium, 29 May 2017, 7am CEST - BONE THERAPEUTICS (Euronext Brussels and Paris:BOTHE), the bone cell therapy company addressing high unmet medical needs in orthopaedics and bone diseases, today announces the appointment of Steve Swinson and Damian Marron to its Board of Directors as Non-Executive Directors.

    The appointments of Steve Swinson and Damian Marron, effective 26 May 2017, complement an already strong Board of Bone Therapeutics bringing in specific public company, orthopaedic and cell therapy understanding and expertise and will provide ongoing support to the leadership team. Steve Swinson and Damian Marron will replace Jacques Reymann and Jean-Jacques Verdickt.

    Steve Swinson has served in a number of senior roles in orthopaedic medical technology and electronics companies, including general management, senior strategy, sales, marketing and commercial operation positions at Medtronic International, a global leader in medical technology. At Medtronic, he led the Spine and Biologics division for Canada and Western Europe, and was Vice President and General Manager for the international spine divison with substantial revenue responsibility. In a 30 year international business career covering Asia, US, Europe and Africa, he has also held senior positions at the diagnostic and medical departments of the blue chip engineering multinationals, General Electric and Hewlett Packard. Steve has a PhD in electrical engineering from the University of Manchester and a MBA from the University of Chicago.

    Damian Marron is an experienced life sciences executive with a successful track record of value creation through public and venture capital financing, portfolio planning and turnaround, M&A, licensing agreements and research and marketing collaborations. He has particular competencies in cell therapy, immuno-oncology and orphan diseases. Damian served most recently as Chief Executive Officer of Agalimmune and has also served as Chief Executive Officer of TxCell, a France-based specialist in personalised T-cell immunotherapies, where he led the Company's IPO on Euronext Paris. As Chief Executive Officer of Trophos, France, he helped raise EUR 34 million in financing and positioned the company for a subsequent acquisition by Roche for EUR 700 million. Damian also served as Executive Vice President, Corporate Development, for NiCox, where he supported the CEO in financing rounds raising over EUR 175 million.

    Michel Helbig de Balzac, Chairman of Bone Therapeutics, commented: "We are delighted to welcome Steve and Damian to the Board of Bone Therapeutics. Their collective track record in leadership and value creation in the healthcare sector and their industry knowledge and expertise in orthopaedic medical technology and cell therapy respectively will be a major asset to the Company. They will be a valuable sounding board to the leadership team as it focuses on advancing our innovative allogeneic cell therapy platform towards commercialization. We would like to thank Jacques Reymann and Jean-Jacques Verdickt for their many years of dedication to Bone Therapeutics and wish them the best in their well-deserved retirement."

    Commenting on his appointment, Steve Swinson said: "Bone Therapeutics leads the field in regenerative approaches to orthopaedics and bone diseases, and its allogeneic cell therapy platform has the potential to transform medicine in these areas. I'm delighted to have the opportunity to use my deep experience in orthopaedic medical technology to help support this Company as it advances its technology towards commercialization."

    Damian Marron added: "I am very excited to be joining Bone Therapeutics. I look forward to bringing my experience in strategic development and my expertise in cell therapy to support the Company as it approaches key value inflection points with its innovative allogeneic cell therapy platform."

    About Bone Therapeutics

    Bone Therapeutics is a leading cell therapy company addressing high unmet needs in orthopaedics and bone diseases. Based in Gosselies, Belgium, the Company has a broad, diversified portfolio of bone cell therapy products in clinical development across a number of disease areas targeting markets with large unmet medical needs and limited innovation.

    Our technology is based on a unique, proprietary approach to bone regeneration which turns undifferentiated stem cells into "osteoblastic", or bone-forming cells. These cells can be administered via a minimally invasive procedure, avoiding the need for invasive surgery.

    Our primary clinical focus is ALLOB®, an allogeneic "off-the-shelf" cell therapy product derived from stem cells of healthy donors, which is in Phase II studies for the treatment of delayed-union fractures and spinal fusion. The Company also has an autologous bone cell therapy product, PREOB®, obtained from patient`s own bone marrow and currently in Phase III development for osteonecrosis and non-union fractures.

    Bone Therapeutics` cell therapy products are manufactured to the highest GMP standards and are protected by a rich IP estate covering nine patent families. Further information is available at: www.bonetherapeutics.com.

    Read more: www.nasdaq.com/press-release/bone-the...
  7. +brammeke 8 juni 2017 23:25

    • +brammeke

      Lid sinds: 10 feb 2011

      Laatste bezoek: 18 apr 2024

    • Aanbevelingen

      Ontvangen: 50

      Gegeven: 30

    •    Aantal posts: 433

    Bone Therapeutics SA : completes patient recruitment for pivotal interim analysis of Phase III Osteonecrosis trial with PREOB®


    08 juni 2017 07:00
    Regulated information
    Bone Therapeutics completes patient recruitment for pivotal interim analysis of Phase III Osteonecrosis trial with PREOB ®
    Positive results could lead to further validation of Company's bone-cell therapy platform
    Results of interim data analysis expected Q3 2018
    Gosselies, Belgium, 8 June 2017, 7am CEST - BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the bone cell therapy company addressing high unmet medical needs in orthopaedics and bone diseases, today announces that it has completed the recruitment of the 44 treated patients required for the planned interim analysis of the Phase III trial for the treatment of osteonecrosis of the hip with its autologous bone cell therapy product, PREOB ® . If results from this interim analysis, based on a 12-month follow up of patients document a strong efficacy signal for PREOB ® , the study recruitment could be terminated prematurely. Results from the 12-month follow up are expected in Q3 2018.
    The interim analysis will be based on an updated clinically relevant endpoint, endorsed by the European Medicines Agency, which reflects the value added to patients and uses a composite responder analysis combining the original co-primary variables, without impacting the design and data collection of the study. This more stringent primary endpoint criterion in the revised analysis has enabled a reduction of the number of patients to be enrolled, to 118 from 130. Also, as stated in the protocol approved by the Competent Authorities in the countries where the study is being conducted, a strong efficacy signal at the interim analysis could enable the early termination of the study. The study is underway at centres in Belgium, France, Germany, the Netherlands and the United Kingdom.
    The Phase III study is a randomized, double-blind, placebo-controlled pivotal trial that aims to confirm the safety and efficacy of PREOB ® in early-stage osteonecrosis of the femoral head over a 24-month period. The patients received either a single administration of PREOB ® , or a placebo into the necrotic lesion using a core decompression procedure. Results from an earlier exploratory Phase IIB osteonecrosis study, presented at the Annual European Congress for Rheumatology (EULAR) in June 2016, demonstrated a strong and prolonged improvement in pain and function as well as a reduction in fracture risk after treatment with PREOB ® compared to standard of care.
    Osteonecrosis is a rare but severe and painful orthopaedic condition characterised by the death of bone tissue, eventually causing the bone to fracture. The most common form of osteonecrosis occurs in the hip where the disease causes femoral head collapse and joint destruction. If left untreated, the condition ultimately requires a total hip replacement but, due to the age of people affected (typically between 30 and 50) hip replacement is not an appropriate long-term solution due to the limited lifespan of prostheses.
    Thomas Lienard, CEO of Bone Therapeutics, commented: "PREOB ® has provided critical proof of concept for Bone Therapeutics in the development of its unique bone cell therapy platform. The completion of recruitment for the interim analysis in the PREOB ® Phase III osteonecrosis trial is an important step in the validation of our platform, which is now in advanced clinical development for our off-the-shelf, allogeneic product ALLOB ® . We look forward to announcing the outcome of the interim study in Q3 2018, following the completion of the twelve-month follow-up period and the potential to bring a new treatment option to patients suffering from this debilitating orphan disease."
    "We are proud to have treated the 44 patients needed for the interim analysis of the PREOB ® Phase III trial in osteonecrosis," commented Miguel Forte, Chief Medical Officer of Bone Therapeutics. "The new, robust optimised analysis we have adopted is more relevant from a patient outcome and clinical benefit perspective, compared with the initial approach and could enable us to reach an outcome with fewer patients, accelerating the progress of the study."
    About Bone Therapeutics
    Bone Therapeutics is a leading cell therapy company addressing high unmet needs in orthopaedics and bone diseases. Based in Gosselies, Belgium, the Company has a broad, diversified portfolio of bone cell therapy products in clinical development across a number of disease areas targeting markets with large unmet medical needs and limited innovation.
    Our technology is based on a unique, proprietary approach to bone regeneration which turns undifferentiated stem cells into "osteoblastic", or bone-forming cells. These cells can be administered via a minimally invasive procedure, avoiding the need for invasive surgery.
    Our primary clinical focus is ALLOB ® , an allogeneic "off-the-shelf" cell therapy product derived from stem cells of healthy donors, which is in Phase II studies for the treatment of delayed-union fractures and spinal fusion. The Company also has an autologous bone cell therapy product, PREOB ® , obtained from patient`s own bone marrow and currently in Phase III development for osteonecrosis and non-union fractures.
    Bone Therapeutics` cell therapy products are manufactured to the highest GMP standards and are protected by a rich IP estate covering nine patent families. Further information is available at: www.bonetherapeutics.com .
  9. +brammeke 9 juni 2017 19:39

    • +brammeke

      Lid sinds: 10 feb 2011

      Laatste bezoek: 18 apr 2024

    • Aanbevelingen

      Ontvangen: 50

      Gegeven: 30

    •    Aantal posts: 433

    gaat lekker. Bij tussentijdse "dip" koop ik 4 de pakketje bij.Nog steeds de "kleinste" in mijn port. Gem. nu aan 7,75.Verwacht er erg veel van, maar op dit ogenblik NOG groter "risico" dan mdxh, ablx, bcart.De "echte" doorbraak verwacht ik niet voor 2020. Bij geen uitbraak uitbraak WO 3, denk ik aan koersen 40-50euro.
    Lees meer op: beursig.com/forum/viewtopic.php?f=4&a...
  15. [verwijderd] 12 juni 2017 17:55

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Dan is 12 niks . maar dan moet alles wel meezitten . Na de rode dag op de beurs van brussel is dit de sterkste stijger hopelijk komen er nog zo vele weken en jaren van dit aandeeltje word het ne topper en kunnen we paar keer verdubbelen
  16. tony0001 12 juni 2017 18:01

    • tony0001

      Lid sinds: 14 mei 2015

      Laatste bezoek: 08 apr 2024

    • Aanbevelingen

      Ontvangen: 5

      Gegeven: 0

    •    Aantal posts: 35

    gemiddeld: 7,45002
    verdubbeling op korte termijn zit er niet in;
    met 10% extra deze zomer zou ik al heel tevreden zijn ....
  17. tony0001 13 juni 2017 10:00

    • tony0001

      Lid sinds: 14 mei 2015

      Laatste bezoek: 08 apr 2024

    • Aanbevelingen

      Ontvangen: 5

      Gegeven: 0

    •    Aantal posts: 35

    Ik zie op Bolero altijd veel kleine orders verschijnen van 10, 11 en 12 stuks aan een koers van vandaag rond de10,5 euro. Iemand een verklaring voor die kleine orders. zelf betaal ik 15 euro om een order uit te voeren. Als dit voor deze orders ook zo is, dan kun je daar toch zelden winst op maken vermoed ik? +1,5 per aandeel om te kopen en idem om te verkopen. Of zie ik dit verkeerd.
  18. [verwijderd] 13 juni 2017 16:07

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Toch krijg ik de indruk dat ze de koers aan het oppompen zijn voor een aanstaande emissie,ik heb dit meer gezien.Want geld hebben ze snel nodig of ze moeten een lening sluiten of een super deal met een partner
  19. +brammeke 13 juni 2017 17:54

    • +brammeke

      Lid sinds: 10 feb 2011

      Laatste bezoek: 18 apr 2024

    • Aanbevelingen

      Ontvangen: 50

      Gegeven: 30

    •    Aantal posts: 433

    kanaalz.knack.be/beurs/z-beurs-1 ... 64901.htmlZie nieuwsbericht vorige week ( 08/06/2017).Laatste nieuws kort:Studie osteonecrose mag "misschien" vervroegd afgesloten worden 3de kwartaal 2018.Zal dan hun 1 ste produkt op de markt zijn.2de kwartaal 2018 zal waarschijnlijk het geld op zijn.Blijf erbij, als alles goed blijft verlopen, de echte grote doorbraak 2019-2020.
319 Posts
Pagina: «« 1 2 3 4 5 6 ... 16 »» | Laatste |Omhoog ↑

Neem deel aan de discussie

Word nu gratis lid van Beursduivel.be

Al abonnee? Log in
Premium

Benieuwd naar onze analyses en kooptips?

Word nu abonnee van BeursDuivel en krijg onbeperkt toegang tot onze (koop)tips en succesvolle modelportefeuilles. Nu 3 maanden voor slechts €19,95! Profiteer van 55% korting!

Word abonnee

Laatste Nieuws

  1. Brusselse beurs beperkt verlies
  2. Must read: Apple worstelt in China
  3. Royal Unibrew verhoogt outlook
  4. Beursblik: prima eerste kwartaal voor WDP
  5. Kepler haalt Euronav van de kooplijst
  6. Bel20 duikt in het rood
  7. Umicore haalt €499 miljoen op met obligaties
  8. Deutsche Bank haalt Rheinmetall van kooplijst
  9. Brussel lager van start door vrees voor escalatie in Midden-Oosten
  10. Britse detailhandelsverkopen onveranderd
  11. Duitse producentenprijzen verder gedaald
  12. Sterke winstgroei WDP in eerste kwartaal

Meest Gelezen Premium

  1. Premium Premium
    Is Just Eat Takeaway ondergewaardeerd?
  2. Premium Premium
    Vooruitblik: aftrap cijferseizoen, einde bankenfeestje en CVC naar het Damrak
  3. Premium Premium
    Ingaan of niet op het bod op de Rabobank Certificaten?
  4. Premium Premium
    Vooruitblik eerstekwartaalcijfers ASML
  5. Premium Premium
    Energie-expert Jilles van den Beukel: "Je moet niet raar opkijken als Shell wordt overgenomen"
  6. Premium Premium
    Orderintake ASML doet even pijn, maar verandert dit iets aan de beleggingscase?
  7. Premium Premium
    Jitse Groen: ‘Het is niet gek dat er interesse is om ons van de beurs te halen’

Macro & Bedrijfsagenda

  1. 19 april

    1. Japan inflatie maart 2,7% YoY volitaliteit verwacht
    2. WDP Q1-cijfers
    3. EU producentenprijzen maart
    4. VK detailhandelsverkopen maart
    5. Fra ondernemersvertrouwen april
    6. KPN €0,098 ex-dividend
    7. CM.com jaarvergadering
    8. NSI jaarvergadering
    9. American Express Q1-cijfers

  2. 22 april

    1. NL investeringen februari
de volitaliteit verwacht indicator betekend: Market moving event/hoge(re) volatiliteit verwacht
Naar de hele agenda